New hope for kids with rare blood disease: trametinib trial opens
NCT ID NCT04943224
First seen Mar 28, 2026 · Last updated May 13, 2026 · Updated 8 times
Summary
This study is for children with a rare blood disorder called histiocytosis that hasn't responded to standard treatments. It tests different doses and timing of the drug trametinib to find the best way to control the disease. The goal is to improve how long children stay free of cancer progression or relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mother and Child Institute
RECRUITINGWarsaw, Mazovian, 01-211, Poland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.